| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 10,190 | 21,770 | 66,710 | 60,770 | 29,230 |
| Sales Growth | -53.19% | -67.37% | +9.77% | +107.90% | -63.68% |
| Net Income | -55,640 | -53,530 | -8,190 | -61,220 | -62,480 |
| Net Income Growth | -3.94% | -553.60% | +86.62% | +2.02% | +14.52% |
Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.
Fiscal Year End Date: 12/31